ArticleFrontiers in endocrinology2022
A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Pertuzumab and Pathological Complete Response in Early HER2+ Breast Cancer: A Systematic Review and Meta-analysis of Real-World Studies.Asian Pacific journal of cancer prevention : APJCP · 2026Pooled it
- Development and internal validation of a nomogram for predicting neoadjuvant therapy efficacy in breast cancer based on the HALP score.Translational cancer research · 2026Article
- Development of a nomogram for predicting axillary pathologic complete response after neoadjuvant therapy in clinically node-positive breast cancer.Frontiers in oncology · 2026Article
- The development and validation of a risk stratification system for assessing axillary status after neoadjuvant therapy in node-positive breast cancer: a multicenter, prospective, observational study.International journal of surgery (London, England) · 2025Observational
- Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment: A Register-Based Study.Annals of surgical oncology · 2024Article
- Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients.Cancer immunology, immunotherapy : CII · 2024Article
- Review
- Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvant systemic therapy in breast cancer.International journal of medical sciences · 2024Article
- Clinical and pathological features analysis of invasive breast cancer with microcalcification.Cancer medicine · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant systemic therapy (NST) could make some clinically node-positive (cN+) breast cancer patients achieve axillary pathologic complete response (pCR). This study aimed to identify the patients who are likely to achieve axillary pCR and help surgeons make surgical decisions on the axilla. Methods: The cN+ breast cancer patients who received NST from 2015 to 2021 at The First Affiliated Hospital of Nanjing Medical University were enrolled. Univariate and multivariate logistic regression analyses were performed, and a nomogram was constructed based on the results of multivariate logistic regression analysis to predict the probability of axillary pCR and validated. Results: The axillary pCR was achieved in 208 (38.7%) patients. Patients who had a higher radiological response rate of breast tumor ( Conclusion: A nomogram was constructed to predict the axillary pCR of cN+ patients receiving NST based on baseline and efficacy indicators to assist surgeons in making surgical decisions on the axilla.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.